EVGN
Evogene Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$0.54
−0.02%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.3M | 3.9M | 5.6M | 3.0M | 1.7M |
| Cost of Revenue | 2.9M | 4.1M | 2.4M | 1.5M | 909.0K |
| Gross Profit | (1.6M) | (241.0K) | 3.2M | 1.5M | 766.0K |
| Operating Expenses | |||||
| R&D Expense | 6.3M | 8.0M | 12.5M | 16.2M | 20.8M |
| SG&A Expense | 5.4M | 5.8M | 9.0M | 7.5M | 10.4M |
| General & Admin Expense | 4.5M | 5.6M | 8.8M | 7.4M | 10.3M |
| Selling & Marketing Expense | (235.0K) | 185.0K | 224.0K | 162.0K | 132.0K |
| Other Expenses | 198.0K | 37.0K | 514.0K | — | (3.5M) |
| Total Operating Expenses | 11.9M | 13.8M | 22.0M | 23.7M | 27.7M |
| Cost and Expenses | 14.8M | 17.9M | 24.4M | 25.2M | 28.6M |
| Operating Income (EBIT) | (13.5M) | (14.0M) | (18.8M) | (22.2M) | (26.9M) |
| Non-Operating | |||||
| Interest Income | 3.0M | 2.5M | 957.0K | 1.2M | 182.0K |
| Interest Expense | 4.9M | 1.9M | 124.0K | 171.0K | 241.0K |
| Net Interest Income | (1.9M) | 575.0K | 833.0K | 1.1M | (59.0K) |
| Other Non-Op Income/Expense | (2.0M) | 536.0K | 4.0M | 285.0K | (2.8M) |
| Non-Operating Income (excl Interest) | (67.0K) | (693.0K) | (4.1M) | (399.0K) | 2.6M |
| EBT (Pre-Tax Income) | (15.6M) | (13.5M) | (14.8M) | (21.9M) | (29.8M) |
| Income Tax Expense | 5.0K | 1.0K | 9.0K | 19.0K | 90.0K |
| Bottom Line | |||||
| Net Income | (9.1M) | (8.5M) | (16.5M) | (23.9M) | (26.6M) |
| Earnings from Cont. Ops | (15.6M) | (13.5M) | (14.8M) | (22.0M) | (29.8M) |
| Earnings from Discont. Ops | 7.7M | 5.7M | (3.2M) | (4.0M) | — |
| Bottom Line Net Income | (9.1M) | (8.5M) | (16.5M) | (23.9M) | (26.6M) |
| Per Share | |||||
| Basic EPS | ($0.91) | ($1.08) | ($2.89) | ($5.23) | ($6.46) |
| Diluted EPS | ($0.91) | ($1.08) | ($2.89) | ($5.23) | ($6.46) |
| Revenue Per Share | $0.11 | $0.49 | $0.98 | $0.65 | $0.41 |
| Shares | |||||
| Basic Shares Outstanding | 12.2M | 7.9M | 5.7M | 4.6M | 4.1M |
| Diluted Shares Outstanding | 12.2M | 7.9M | 5.7M | 4.6M | 4.1M |
| Profitability Metrics | |||||
| EBITDA | (12.6M) | (12.2M) | (13.4M) | (20.5M) | (27.0M) |
| D&A | 895.0K | 1.1M | 1.4M | 1.3M | 2.6M |
| EBIT | (13.5M) | (13.3M) | (14.7M) | (21.8M) | (29.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026